Abstract There has been considerable recent interest in the genetic, biological and epidemiological basis of mammographic density (MD), and the search for causative links between MD and breast cancer (BC) risk. This report will critically review the current literature on MD and summarize the current evidence for its association with BC. Keywords 'mammographic dens*', 'dense mammary tissue' or 'percent dens*' were used to search the existing literature in English on PubMed and Medline. All reports were critically analyzed. The data were assigned to one of the following aspects of MD: general association with BC, its relationship with the breast hormonal milieu, the cellular basis of MD, the generic variations of MD, and its significance in the clinical setting. MD adjusted for age, and BMI is associated with increased risk of BC diagnosis, advanced tumour stage at diagnosis and increased risk of both local recurrence and second primary cancers. The MD measures that predict BC risk have high heritability, and to date several genetic markers associated with BC risk have been found to also be associated with these MD risk predictors. Change in MD could be a predictor of the extent of chemoprevention with tamoxifen. Although the biological and genetic pathways that determine and perhaps modulate MD remain largely unresolved, significant inroads are being made into the understanding of MD, which may lead to benefits in clinical screening, assessment and treatment strategies. This review provides a timely update on the current understanding of MD's association with BC risk.
Introduction
Mammographic density (MD) and its association with breast cancer risk On a mammogram, stromal and epithelial tissues are thought to attenuate x-rays more than adipose tissues. Mammographic density (MD) describes the extent of white or radio-opaque tissue (dense area) on a mammogram, and the term percent MD (PMD) is used to represent this dense area as a proportion of the total tissue area of the breast on a mammogram [1] . Published literature on MD since 2007 have been provided in Tables 1, 2 , 3, 4, 5, 6, 7, 8, and 9, using a format adapted from McCormack et al. [2] who provided a comprehensive review at that time.
Historically, the concept that certain aspects of the appearance of a mammogram were associated with breast cancer (BC) risk was first proposed by Wolfe et al. in 1976 , who described four different breast parenchymal patterns [3] . Since then, many case-control studies, usually nested within a screening cohort, have consistently confirmed that after adjusting for age and BMI, MD as measured by Wolfe patterns and other methods, are risk factors for BC [2, 4] . Conventional classification methods include the Breast Imaging Reporting and Data system (BIRADS) [5] , Wolfe [3] and Tabár [6] systems, and the novel Cumulus technique [7] . The specifics of which are detailed in Table 10 . The increased risk associated with age-and BMI-adjusted MD as measured by Cumulus is about 40 % per standard deviation, whether it be the dense area or the PMD [8] . The adjustment for age and BMI is necessary because MD decreases with age, and more strongly with body mass index (BMI). BC risk, however, increases with age and, for women of population screening age, with BMI, and this is more critical for PMD than for dense area [9] . Therefore, the case-control studies have adjusted for this 'negative confounding', a point that needs to be remembered when interpreting the analyses. Not only is high BMI associated with increased non-dense area in the breast, which is a fat storage site [10] [11] [12] [13] , but also has been found to negatively correlate with absolute dense area in many [14] [15] [16] [17] but not all studies [11, 12, 18] . The reason for this possible inverse relationship is unclear. It is hypothesized that androgens derived from increased adiposity may play a role in reducing fibroglandular components [19] or high BMI stimulates the differentiation of stromal preadipocytes into fat rather than collagen [20, 21] .
Studies have shown that BC arising within areas of high MD is more commonly associated with factors indicative of a poor prognosis, including large tumour size, high histological grade, lympho-vascular invasion (LVI) and advanced stage, compared to those arising within low MD tissue [22] [23] [24] . Although this would suggest that high MD is associated with poor BC survival, two large retrospective studies using BIRADS found no association between MDand BC-specific survival [25, 26] . The reason that high MD tumours have more aggressive features compared with low MD tumours remains elusive, although it is plausible that factors influencing the initiation of BC differ from those that affect prognosis once cancer progresses, or that MD influences on BC survival are nullified by current treatment approaches. Mammographic density appears also to be associated with increased local recurrence and the risk of a second primary BC. Using the Wolfe classification of MD adjusted for age at diagnosis but not BMI, women with higher MD have a greater risk of local recurrence, particularly those who did not receive adjuvant radiotherapy following breast-conserving surgery (BCS) [27] . In addition, a recent study of 607 cases with almost 13 years of follow-up [25] found that higher MD, corrected for age and BMI and measured by Cumulus, was associated with a worse outcome for women who did not receive radiotherapy post-BCS. Moreover, higher MD was also found to be associated with an increased risk of a second BC. In another study with 5 years of follow-up, Buist et al. [28] found that BCS without radiation was associated with an increased risk of recurrence, and women with higher MD, measured by BIRADS, had a greater risk of a second primary, but not of a local recurrence. However, an interaction between radiation therapy and MD was not examined, and only 353 women had MD measured, so the sample size might have been too small to detect an association between MD and local recurrence. It is worthwhile noting that although BC arising from high MD areas has been found to demonstrate more aggressive features, most studies did not adjust for tumour size, LVI, nuclear grade and stage when examining the relationship between MD and local recurrences [27] [28] [29] [30] (see Table 3 ).
MD and the breast hormonal milieu
The use of HRT appears to increase MD. A Norwegian study of 2,424 postmenopausal women found that MD was higher for women currently using combined progestogen and oestrogen therapy (E ? P HRT) than for former or non-users [31] , and the use of high-dose norethisterone acetate (NETA) was particularly associated with higher MD. These findings are consistent with other published studies [32] [33] [34] , in which Greendale et al. and Persson et al. observed higher MD for E ? P HRT users in large Caucasian population studies [32, 33] . A smaller decline in MD with ageing was found for E ? P HRT users compared with non-users by a combined Dutch and British study [34] . Furthermore, the association between E ? P HRT use and PMD was stronger for women who later developed BC [35] . In a review of 80,867 mammograms from 39,296 postmenopausal women, oestrogen-alone HRT was found to be associated with higher MD, although the association was not as strong as that seen with combined HRT and MD [36] .
Parity is inversely associated with MD, with a decrease of about 10 % of the standard deviation of MD measures adjusted for age and BMI, per live-birth [9] . This is equivalent to about a 4 % decrease in risk per birth that could be attributed to a decrease in MD, should the association be causal. Studies of the association between lactation and MD have to date produced conflicting results [37, 38] . A longitudinal study of 2,000 women found that breastfeeding was inversely associated with PMD [37] . Using a xenograft model of human mammary tissue, Chew et al. observed that high MD human tissues have less stromal and more adipose components after murine postpartum involution or lactation [39] . However, the biological rationale behind these observations remains unclear. Since MD might be reduced by the cessation of HRT and parity, and increases with HRT use, it is possible that MD is modulated by endogenous and exogenous hormonal exposures. For this reason, it has been proposed that tumours occurring in women with high MD are more likely to be oestrogen receptor (ER) or progesterone receptor (PR)-positive than those diagnosed in non-dense tissue [40, 41] . However, Antoni et al. [42] performed a meta-analysis of 7 cohort and 12 case-control studies and found that the magnitude of the association between MD and BC of differing subtypes was similar. This finding is consistent with that of a Spanish study of 1,172 women, in which the strength of association of MD was not found to differ with BC subtypes based on their hormonal receptor status [43] . The reason for this observation, as hypothesized by some authors, could be that MD occurs secondary to long-term tissue-specific inflammation as a result of cumulative exposure to environmental factors such as androgen and oestrogen, which are associated with an increased risk of both ER-positive and ER-negative tumours [44] [45] [46] [47] . Refuting this hypothesis, a case-only study of 2,410 women reported an inverse association between MD and ER expression [48] . This was surprising considering MD has been associated with both extrinsic and intrinsic hormonal exposures such as HRT and parity. Despite the lack of an association between MD and ER-positive BC, MD was found to be positively associated with PR expression by the same study [48] . Research using mouse models [49, 50] has shown that proliferation of mammary stem cells was under the influence of progesterone, which could underpin the MD associations. In addition, the association between MD and BC risk is not found to differ by human epidermal growth factor receptor (HER2) status in published population studies [23, 43, 51] .
The cellular basis of MD Mammographically dense breast tissues have a higher composition of stroma, higher relative gland counts and a lower proportion of fat than low MD counterparts [52, 53] . Since high MD tissues have been positively associated with stromal and epithelial proliferation [54] [55] [56] [57] , investigations of cell proliferation markers such as Ki-67 have been performed, but most studies did not find any association between Ki-67 expression and MD [22, 58, 59] . The only positive association was reported by Harvey et al., who examined the benign breast tissue of 56 postmenopausal women and found that higher MD was associated with increased Ki-67 activity [60] . In another study of 783 premenopausal and 436 postmenopausal women [61], mitogenic factors implicated in tumour development and progression, such as insulin-like growth factor-1 (IGF-1), insulin-like growth factor-binding protein-3 and growth hormone (GH), were examined from blood samples using ELISA assays, and were not found to be associated with MD.
The breast tissue stroma is composed of ECM proteins, adipocytes, fibroblasts and immune cells. CD-36, a transmembrane receptor that modulates many stromal processes including adipocyte differentiation, apoptosis and cell-ECM interactions, was reduced in multiple cellular compartments within the stroma of high MD tissues compared with low MD tissues [62] . DeFilippis et al. [62] found the level of CD-36 expression to be minimal in many cell types of mammary tumour stroma compared with nonmalignant tissues in the same breast. It would be valuable for future studies to examine the association between CD-36 and MD, and to assess its potential as a possible target for MD-associated BC prevention.
Higher MD has often been associated with increased collagen content and ECM stiffness [38, 63, 64] . This is potentially driven by macrophages, which promote collagen fibrillogenesis in the mouse mammary gland [65] , and by tissue metalloproteinase-3 (TIMP3)-mediated inhibition of matrix degradation [66] ; however, there are likely to be many other environmental and genetic regulators, some of which are discussed in the following section. Increased ECM stiffness has been shown to promote the focal adhesion kinase-Rho-extracellular signal-related kinase (FAK-Rho-ERK) signalling network to stimulate cell proliferation, and consequently results in a malignant phenotype of mouse mammary epithelial cells [67] . The authors have proposed a causal relationship between higher MD and BC tumourigenesis. Supporting this, dense matrix associated with MD has been found to raise Rho-associated coiled-coil containing protein kinase 1 (ROCK1) activity, which plays a role in cell migration [68] . In addition, our collaborators have shown that dense matrices of collagen (20 mg/cm 3 ), similar in concentration to that found in dense connective tissue associated with high MD, stimulated ameboid-like cell migration of human BC cells [69] . The presence of such ameboid-like cells in dense connective tissue surrounding invasive ductal carcinomas has been tentatively associated with local recurrence [69] . The dense collagen network could also serve to increase migration of tumour-associated macrophages [70] , which promote tumour progression and metastasis [71] .
Given the complex interplay between the epithelial, stromal and ECM compartments in the breast microenvironment, as summarized in Fig. 1 , a robust animal model could help clarify the molecular mechanisms of MDassociated malignancy risk. Indeed, mammary glands from genetically altered mice have been used to examine MDlike phenotypes in vivo [72] , and we recently developed a novel model, where high and low MD human breast tissues implanted in separate murine biochambers supported by the inferior epigastric pedicles maintained their viability and MD phenotype [73] .
Genetic factors and variation in MD measures that predict BC
In 1987, a small within-pair twin study using BIRADs measures showed that MD measurements were correlated Non-dense area = whole breast areadense area in twin pairs, but was not powered to address the hypothesis that this was due to genetic factors by testing if monozygotic (MZ) pairs were more highly correlated than dizygotic (DZ) pairs [74] . MD risk-associated measures based on CUMULUS were found to be correlated in sister and mother-daughter pairs [75] , but a nuclear family design alone cannot differentiate genetic from shared environmental factors as causes of familial correlation. The breakthrough publication in this regard came in 2002 when two large twin studies, one conducted in Australia and the other in North America, demonstrated that MZ pairs were about twice as correlated as DZ pairs, consistent with genetic factors explaining about 60 % of the variance in the CUMULUS measures that predict BC risk [76, 77] . The study was also remarkable in finding highly consistent results in terms of variances and MZ and DZ pairs co-variances across Caucasian women from the two continents.
While studies of common variants (polymorphisms) in candidate genes based on biological arguments identified some putative associations, these were not conclusive. The next major advance came from studies of single nucleotide polymorphisms (SNPs) found to be associated with BC risk by genome-wide association studies (GWAS) [78] . The findings of the twin study above were consistent with a small overlap in BC and MD genes, and this was borne out by a nested case-control study which predicted that there would be about a 14 % overlap (95 % CI 4-39) [79] .
Early attempts to examine if these BC associated SNPs were also associated with the MD measures that predict BC risk failed to find convincing evidence. A larger Australian study of twins and sisters showed that, taken as a group, the 12 BC susceptibility SNPs studied were more strongly associated with MD than would be expected by chance [80] . In particular, the SNP rs3817198 in the region of the LSP1 gene was significantly associated with dense and percent dense area.
A pooled cross-sectional study by the DENSNP consortium confirmed the association described above with the LSP1 region SNP, and also found evidence that a SNP in the region of RAD51L1 was implicated in MD [81] . A meta-analysis of five GWAS of MD measures by the MODE consortium found that the SNP rs10995 in the region of ZNF365, which had been shown to be associated with BC risk [82] , was also associated with MD. Another GWAS implicated SNPs in a region on chromosome 12q24 [83] . Further studies by the MODE and DENSP consortiums are being conducted.
In summary, around 10 % of common SNPs associated with BC risk are also associated with the MD measures that predict BC risk, but to date these explain only a few percent of the variance. MD is likely to be affected by a Fig. 1 
Translation of MD into the clinical setting
To date, MD has not been reported systematically in the clinical setting due to the lack of an automated tool. Conventionally, assessments of MD are based on subjective reporting of mammographic parenchymal patterns, which can be time consuming and examiner dependent. Since these measures were not specifically designed for the purpose of selecting women at increased risk of developing BC, they may not be appropriate for incorporation into population screening programs. The current trend of moving from film-based screening mammograms to digital ones has enabled alternative approaches to be developed, such as calibrated planar and volumetric measures, and automated variation measure [85] [86] [87] , in the hope of achieving efficient and standardized reporting that is comparable across studies. The aforementioned Cumulus has been validated by epidemiological studies and is currently considered to be the gold standard for measuring MD and predicting BC risk [88] , with greater intra-observer reliability than BIRADS [89] . An automated version of Cumulus, AutoDensity, that could be suitable for digital mammography has recently been developed [90] . Despite the need for more studies to validate the novel MD assessment techniques, these automated approaches may hold the key to risk stratification in future screening, while reducing the time and cost of acquiring MD data.
MD can represent a preventative and therapeutic target. In the primary prevention IBIS-1 trial, women who received tamoxifen prophylaxis-and had a minimum of 10 % reduction in MD in the first 1.5 years of taking tamoxifenwere found to have a 63 % reduction in BC risk, whereas no effect on BC risk was observed for those women who had a less than 10 % decrease in MD [91] . In addition, a recent retrospective study of 974 postmenopausal BC patients with a 15-year follow-up found a relative reduction of 20 % in MD for women who received adjuvant tamoxifen, and this MD reduction was associated with a 50 % risk reduction of BC-specific mortality [92] . Furthermore, Kim et al. [93] found that changes in MD predicted recurrences in 1,065 women with ER-positive BC who were treated with tamoxifen for at least 5 years with recurrence more than doubled in women with no change in MD compared with those who had at least a 10 % decrease in MD. However, MD was not adjusted for BMI, which is inversely associated with MD but directly associated with BC risk in this age group. Paradoxically, 18 % of these women had increased MD postendocrine therapy for reasons that are unclear. Overall, reduction in MD as a host response could be an effective and non-invasive biomarker to assess or predict the efficacy of tamoxifen for prevention and treatment. Women with dense breasts may benefit from a trial of tamoxifen for 12-18 months to help reduce MD, and therefore their BC risk. However, the current evidence is insufficient to make this recommendation at a population level, given potential side effects of endometrial cancer and thromboembolic events.
The recent mandating of MD reporting in several states in the USA [94] is raising awareness of the role of MD in increasing BC risk. The introduction of this legislation is largely in response to the high-profile campaign by the Density Education National Survivors' Effort (Are you dense?) [95] , which encourages women to ask for an ultrasound (US) or magnetic resonance imaging (MRI) if their breast tissues are reported as heterogenous or dense on mammogram. However, whether this move will improve clinical outcome and be cost-effective without unnecessarily increasing women's anxiety remains to be examined. Breast-screening programs are designed to reduce mortality by detecting BC at an early stage when treatment options may be more effective. Imaging additional to mammography demands a higher level of resources and can produce increased false-positive results; hence, a high MD can play a role in helping select women who need it most. Since the implementation of Connecticut Public Act 09, there have been two recent studies conducted to assess the role of US in detecting BC for women with dense breasts [96, 97] . Both found that US contributed to increased cancer detection yield (an additional cancer detection rate of 3.2 per 1,000 women screened) in women who have dense breasts and normal mammograms, with no additional risk factors. However, manual US is labourintensive and subjective, being radiographer-operated. A newer modality, automated whole breast ultrasound (AWUS), may warrant further investigation as the automation reduces labour and time costs [96, 98] .
While breast MRI has high sensitivity in women with increased benign parenchyma enhancement, the high false-positive rate and cost may render it a less attractive modality for screening in women with high MD [96] . The ACRIN 6666 study confirmed that use of a single screening MRI or addition of annual screening breast US in women with heterogeneously or extremely dense parenchyma in at least one quadrant on mammogram resulted not only in an increased BC detection yield (additional 14.7 cancers with MRI and 3.7 cancers with ultrasound per 1,000 screens) but also increased false-positive findings and higher biopsy rates [99] . Breast tomosynthesis is also available as a diagnostic tool, but its role in screening of high MD women is unclear. There is no evidence to suggest that tomosynthesis is superior to mammogram; on the contrary, digital tomosynthesis has been found to significantly underestimate MD compared to digital mammogram [100] .
A large prospective cohort study of 11,474 women with BC also found that annual mammography screening among women aged 40-49 years who had extremely dense breasts was associated with decreased risk of advanced-stage cancer or large tumour compared to biennial screening in this age group. However, the probability of a false-positive result was high (65.5 %). In addition, annual screening mammography for women aged 50-74 years did not reduce the risk of detecting advanced BC compared to biennial screening, regardless of their MD status [101] .
We propose that women aged 40-74 at the initial screening mammogram with MD in the BIRADS category 4 (extremely dense) or in the C50 % PMD category measured by Cumulus should be considered for additional imaging such as US to help detect early small BC. Consideration should be given as to whether a woman with extremely dense parenchyma C75 % would be recommended for a single screening breast MRI at commencement. These considerations should also take into account the inverse relationship between MD and age/BMI, and the overall risk profile for BC, including family history and exogenous endocrine exposure. Nevertheless, we acknowledge that this is currently a contentious topic, and more studies are warranted to evaluate how MD can be best incorporated into clinical practice.
Conclusion
Research to date has confirmed the importance of MD in BC risk prediction and outcomes, as well as its association with changes in the breast tissue hormonal milieu and heritable factors. However, the evidence suggests that the underlying biological and genetic basis of MD is likely to be complex. Key areas for further investigation include how endogenous steroids affect MD, which could up-or down-regulate cellular signalling pathways that are related to altered BC risk. Although tamoxifen appears to modify MD, this finding needs to be externally validated by further studies and the mechanisms behind this relationship explored. Further clinical and epidemiological studies are also needed to try to determine how to effectively employ MD in a clinical environment. In the future, measurement of MD-especially if it is automated as part of digital mammography for the purpose of personalized medicinemight be used to improve BC screening and treatment strategies.
